 |
|
Search results for tumor
Sen. Ted Kennedy's illness, as well as questions about the possible effects of cell phone use, have kept brain tumors in the news. Dr. Isabelle M. Germano, a neurosurgeon at Mount Sinai who studies brain tumors, offers a primer on detection and treatment. read more »
11 Comments
Add this link to...
Tell a friend
Bury
11 Comments
Add this link to...
Tell a friend
Bury
As professor and chairman of the Neurosurgery Department at Mount Sinai, Bederson oversees 500 benign brain tumor patients a year and 2,000 surgeries. He spoke with us about researching and diagnosing this treatable condition. read more »
12 Comments
Add this link to...
Tell a friend
Bury
12 Comments
Add this link to...
Tell a friend
Bury
A pediatric neurosurgeon says a tumor he removed from the brain of a Colorado Springs infant contained a tiny foot and other partially formed body parts. read more »
13 Comments
Add this link to...
Tell a friend
Bury
13 Comments
Add this link to...
Tell a friend
Bury
WASHINGTON - The days of one-size-fits-all cancer treatment are numbered: A rush of new research is pointing the way to tailor chemotherapy and other care to what's written in your tumor's genes. read more »
11 Comments
Add this link to...
Tell a friend
Bury
11 Comments
Add this link to...
Tell a friend
Bury
All she wants to do is play with her pet dog and hang out with her big sister. A seven-year-old girl who underwent ground-breaking surgery to remove an "inoperable tumor" returned to her Long Island home Tuesday all smiles. read more »
12 Comments
Add this link to...
Tell a friend
Bury
12 Comments
Add this link to...
Tell a friend
Bury
This past week, 17-month-old Claudia Lozada took a life-changing trip to New York City. On Wednesday, the little girl from Puerto Rico checked into Beth Israel Medical Center, where doctors removed a massive benign tumor from her head. read more »
13 Comments
Add this link to...
Tell a friend
Bury
13 Comments
Add this link to...
Tell a friend
Bury
Exelixis Inc. (EXEL)’s experimental pill
reduced malignant growths in the bones of 86 percent of men with
prostate cancer and cut the spread of tumor cells in one-fourth
of women with ovarian cancer in a company study.
The research sought to gauge the effect of the drug called
XL184 on nine cancer types. Based on the findings released
today, Exelixis plans to conduct larger studies in ovarian and
prostate cancer, said Michael Morrissey, the South San
Francisco-based company’s chief executive officer.
13 Comments
Add this link to...
Tell a friend
Bury
« previous1 next »
